244 results on '"Lakshmi, Kavitha M."'
Search Results
2. Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India
3. Endothelial Activation and Stress Index (EASIX) Measured Pre-Transplant Identifies a Subgroup with High Transplant Related Mortality in Patients with Thalassemia Undergoing Stem Cell Transplantation Using Thiotepa-Treosulfan-Fludarabine Conditioning
4. Prospective Evaluation of a Defined Replacement Protocol for Peri-Operative Hemostasis in Patients with Severe Hemophilia Α with and without Inhibitors on Emicizumab Prophylaxis Undergoing Elective Major Surgeries. (EmiSurg Study)
5. Fludarabine and Melphalan Reduced Toxicity Versus a Myeloablative Fludarabine and Busulfan Conditioning Regimen for Acute Myeloid Leukemia
6. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
7. Ehl Factors at Lower Than Standard Dose Achieve Satisfactory Surgical Haemostatsis in Haemophilia
8. Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT
9. Impact of Graft Versus Host Disease on Outcome of Allogeneic Haematopoietic Stem Cell Transplantation for Thalassemia Major - Comparison of Bone Marrow Vs Peripheral Blood Stem Cell Grafts
10. Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia
11. Iron Reduction Therapy in Ex-Thalassemics - Long Term Outcome
12. Outcome of Immune Tolerance Induction Using an Extended Half-Life Clotting Factor Concentrate — Recombinant Factor VIII Fc (Eloctate™) — a Report from India
13. Targeted IV Vs Oral Busulfan in Very Young Children with Thalassemia Major Undergoing Matched Allogeneic Haematopoietic Stem Cell Transplantation
14. Higher Incidence of Graft Rejection in Non-Sibling Fully Matched Related Donor Stem Cell Transplants for Thalassemia Major: A Cautionary Note
15. Haplo-Identical Transplants Using Post Transplant Cyclophosphamide (PTCy) Are Associated with Good Outcomes If Transplanted with Early Disease - a Single Centre Analysis from India
16. Role of Pre-Transplant Cardiac and Hepatic T2* Magnetic Resonance for Risk Assessment in Patients with Thalassemia Major Undergoing an Allogeneic Stem Cell Transplantation
17. Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition
18. Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen
19. Multi-Drug Resistant Organisms Are Common in Fecal Surveillance Cultures and Do Not Predict Bacteremia but Correlate with Poorer Outcomes in Patients Undergoing Allogeneic Stem Cell Transplants
20. A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen
21. Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score
22. Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation
23. Outcome of Allogeneic Stem Cell Transplantation for Thalassemia Major in India
24. Coagulopathy in Acute Promyelocytic Leukemia: Strategies to Improve Assessment of Hemostatic Risk
25. BK Virus Induced Haemorrhagic Cystitis in Haematopoietic Stem Cell Transplant Setting — a 10 Year Retrospective Case Control Study
26. Telomere Length Is Significantly Reduced in Patients with Aplastic Anemia and Is Not Influenced By Gender and Severity
27. Pharmacokinetics of Treosulfan in Patients with Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation — a Comparison of Two Formulations and Correlation with Clinical Outcomes
28. Donor Telomere Length Influences Engraftment and Outcome in Aplastic Anemia Patients Undergoing Matched Related Stem Cell Transplantation
29. Meaningful Reduction of Annual Bleeding Rate with Lower Dose Prophylaxis in Minimally Treated Children with Hemophilia in India
30. Acute Myeloid Leukemia: Challenges and Real World Data from India
31. Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation
32. The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study
33. Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India
34. Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome
35. NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance
36. Delay In Onset Of First Transfusion and Increased Risk Of Graft Rejection In β Thalassemia Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant
37. Clinical Profile and Outcome Of Patients With Graft Rejection Following Related HLA Matched Allogeneic Stem Cell Transplant For β Thalassemia Major
38. Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance
39. A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA)
40. Clinical Profile and Outcomes of Patients with β Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant
41. Response to Immunosuppressive Therapy with Antithymocyte Globulin (ATG) In Older Patients with Aplastic Anemia
42. Final Analysis of a Multi-Center Randomized Controlled Trial (IAPLSG04) to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
43. Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Under Going a HLA Matched Related Allogeneic Stem Cell Transplant with the Use of a Treosulphan Based Conditioning Regimen and Peripheral Blood Stem Cell Grafts
44. Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy
45. Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with β-Thalassemia Major Undergoing Allogeneic HSCT
46. Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia
47. Single Agent Arsenic Trioxide Regimen for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Initial Results of a Multicenter Randomized Controlled Study From India to Study the Optimal Duration of Arsenic Trioxide Maintenance Therapy (IAPLSG04).
48. Risk Stratification without a Liver Biopsy of Patients with β Thalassemia Major Undergoing a Matched Related Allogeneic Bone Marrow Transplant.
49. Polymorphisms in the CYP450 Genes Influences Regimen Related Toxicity and Outcome in Patients with Beta Thalassaemia Major Undergoing HSCT.
50. Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.